Moderna Inc. announced median five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 clinical study. The results demonstrated that intismeran autogene, in combination with KEYTRUDA, continued to show sustained and clinically meaningful improvement in recurrence-free survival for patients with high-risk melanoma following complete resection. The therapy reduced the risk of recurrence or death by 49% compared to KEYTRUDA alone. The safety profile of intismeran autogene in combination with KEYTRUDA remained consistent with previous reports. Data from this study have already been presented. Moderna and Merck currently have eight Phase 2 and Phase 3 clinical trials underway across multiple tumor types, with the Phase 3 INTerpath-001 study for adjuvant melanoma now fully enrolled.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein.